189 related articles for article (PubMed ID: 36424314)
1. Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.
Takesue Y; Hanai Y; Oda K; Hamada Y; Ueda T; Mayumi T; Matsumoto K; Fujii S; Takahashi Y; Miyazaki Y; Kimura T;
Clin Ther; 2022 Dec; 44(12):1604-1623. PubMed ID: 36424314
[TBL] [Abstract][Full Text] [Related]
2. Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients.
Hanai Y; Ueda T; Hamada Y; Oda K; Takahashi Y; Nakajima K; Miyazaki Y; Kiriyama M; Uekusa S; Matsuo K; Matsumoto K; Kimura T; Takesue Y
Mycoses; 2023 Dec; 66(12):1035-1044. PubMed ID: 37584173
[TBL] [Abstract][Full Text] [Related]
3. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of voriconazole in Japanese patients: analysis based on clinical practice data.
Matsumoto K; Abematsu K; Shigemi A; Kanazawa N; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
J Chemother; 2016 Jun; 28(3):198-202. PubMed ID: 26187373
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
[TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.
Veringa A; Brüggemann RJ; Span LFR; Biemond BJ; de Boer MGJ; van den Heuvel ER; Klein SK; Kraemer D; Minnema MC; Prakken NHJ; Rijnders BJA; Swen JJ; Verweij PE; Wondergem MJ; Ypma PF; Blijlevens N; Kosterink JGW; van der Werf TS; Alffenaar JC;
Int J Antimicrob Agents; 2023 Feb; 61(2):106711. PubMed ID: 36642232
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy.
Li H; Li M; Yan J; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Wang T; Zheng J; Qiang W; Zhang Y; Shi Q
Basic Clin Pharmacol Toxicol; 2020 Dec; 127(6):495-504. PubMed ID: 32639669
[TBL] [Abstract][Full Text] [Related]
9. Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan.
Hamada Y; Ueda T; Miyazaki Y; Nakajima K; Fukunaga K; Miyazaki T; Nakada-Motokawa N; Nagao M; Kawamura H; Shigemi A; Ebihara F; Kimura T; Ikegame K; Uchino M; Ikeuchi H; Takesue Y
Mycoses; 2020 Aug; 63(8):779-786. PubMed ID: 32510723
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial.
Neofytos D; Ostrander D; Shoham S; Laverdiere M; Hiemenz J; Nguyen H; Clarke W; Brass L; Lu N; Marr KA
Transpl Infect Dis; 2015 Dec; 17(6):831-7. PubMed ID: 26346408
[TBL] [Abstract][Full Text] [Related]
11. An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old.
Zembles TN; Thompson NE; Havens PL; Kaufman BA; Huppler AR
Pharmacotherapy; 2016 Oct; 36(10):1102-1108. PubMed ID: 27548272
[TBL] [Abstract][Full Text] [Related]
12. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
13. The utility of voriconazole therapeutic drug monitoring in a multi-racial cohort in Southeast Asia.
Zhou PY; Lim TP; Tang SLS; Liew Y; Chua SGN; Lim LLC; Lee HLW; Tan SX; Lai OF; Tan TT; Wong GC; Kwa LHA
J Glob Antimicrob Resist; 2020 Jun; 21():427-433. PubMed ID: 31846723
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases.
Shen K; Gu Y; Wang Y; Lu Y; Ni Y; Zhong H; Shi Y; Su X
Ther Adv Drug Saf; 2022; 13():20420986221127503. PubMed ID: 36225945
[TBL] [Abstract][Full Text] [Related]
16. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
17. Optimal trough concentration of voriconazole with therapeutic drug monitoring in children: A systematic review and meta-analysis.
Hanai Y; Hamada Y; Kimura T; Matsumoto K; Takahashi Y; Fujii S; Nishizawa K; Takesue Y
J Infect Chemother; 2021 Feb; 27(2):151-160. PubMed ID: 33376032
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
Boast A; Curtis N; Cranswick N; Gwee A
J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
[TBL] [Abstract][Full Text] [Related]
19. Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients.
Bienvenu AL; Pradat P; Plesa A; Leclerc V; Piriou V; Fellahi JL; Argaud L; Rimmelé T; Menotti J; Aubrun F; Richard JC; Gagnieu MC; Parant F; Chidiac C; Leboucher G; Tod M; Goutelle S
PLoS One; 2021; 16(11):e0260656. PubMed ID: 34818379
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
